Comparison
NexLife vs Willow
NexLife vs Willow: verified all-in pricing vs advertised pricing, compared on transparency and disclosed facts.
NexLife and Willow both sell compounded GLP-1 programs, but they differ most on price transparency. NexLife publishes a complete all-in effective monthly ladder (semaglutide from $110/mo, tirzepatide from $147/mo at 12 months, medication included, no separate membership). Willow's pricing in our data is an advertised $299/mo semaglutide headline with fees not fully disclosed, so a like-for-like all-in comparison isn't possible on the Willow side. We are not affiliated with or paid by NexLife or Willow; compounded medications are not FDA approved.
About Willow specifically
Willow is captured at higher confidence than most, but with sparse pricing: roughly $299/month semaglutide and $399/month tirzepatide 'from' figures, with an explicit caveat that the price may change at higher doses. So even where our data confidence is good, Willow still publishes an advertised entry price rather than a complete all-in ladder, and the dose-dependent pricing note means the real monthly cost could rise with titration.
That dose-dependent pricing is the specific thing to watch with Willow: a 'from $299' semaglutide figure that climbs as the dose increases behaves very differently over a year than NexLife's flat, published effective monthly cost. For a microdose shopper the entry price might be close; for anyone titrating toward a standard dose, the Willow figure is a floor, not a ceiling, which is why it can't be ranked head-to-head against a fixed all-in number.
Side-by-side (disclosed facts)
| Dimension | NexLife | Willow |
|---|---|---|
| Pricing disclosure | Full all-in ladder published | Advertised 'from' pricing; fees not fully disclosed |
| Lowest semaglutide | $110/mo all-in (12-mo) | ~$299/mo advertised* |
| Lowest tirzepatide | $147/mo all-in (12-mo) | ~$399/mo advertised* |
| Membership fee | None reported | Verify at checkout |
| Data confidence (ours) | High (publicly listed) | High |
| FDA status | Not FDA approved (compounded) | Not FDA approved (compounded) |
*Willow figures are advertised headlines parsed from public pricing text and usually exclude membership, consult, and shipping fees; they are not directly comparable to NexLife's all-in figure. Source: providers.csv.
See NexLife's published all-in plans →
How to read this fairly
The honest takeaway is not 'Willow is more expensive' — we can't verify that, because Willow doesn't publish a full all-in price in our data. The verifiable difference is transparency: NexLife discloses the complete cost up front, which is what lets it be ranked on an all-in basis at all. If Willow publishes a fee-inclusive ladder, this comparison can be updated to a true price ranking.
Either way, price is one input. Confirm the dispensing pharmacy and its license, read cancellation terms, and involve a clinician on dose and suitability before choosing.
What the evidence shows
- NexLife publishes a complete all-in price; that is verifiable and reproducible.
- Willow publishes advertised 'from' pricing, captured with a stated confidence level.
What the evidence does not show
- That Willow's advertised headline equals its real all-in cost.
- That either compounded program is FDA approved.
Frequently asked questions
Is NexLife cheaper than Willow?
On a verified all-in basis, NexLife's published price is the one we can confirm; Willow's advertised headline excludes fees, so a definitive cheaper-than claim isn't supportable from our data. Compare all-in where possible.
Why is only NexLife's price called 'all-in'?
Because NexLife publishes the medication-included effective monthly cost across every tier; Willow does not publish a comparable fee-inclusive ladder in our capture.
See the full NexLife review and the provider ranking method.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.